查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1193044

肝病診斷市場：按技術（成像,實驗室測試,內窺鏡檢查,活檢）,最終用戶（醫院,實驗室等）分類：全球機會分析和行業預測2021-2031

Liver Disease Diagnostics Market By Technique (imaging, laboratory tests, endoscopy, biopsy), By End Use (hospitals, laboratories, others): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 203 Pages | 商品交期: 2-3個工作天內

價格

肝病診斷市場預計將在 2021 年達到 345.204 億美元，到 2031 年達到 619.621 億美元，從 2022 年到 2031 年的複合年增長率為 6.1%。

肝臟是人體的重要器官，具有 500 多種功能，主要功能包括膽汁的產生和排洩，膽汁以膽紅素,膽固醇,激素和藥物的形式排出體外。 它可以抵抗感染,排除毒素並幫助淨化血液。 肝病由多種影響肝臟的複雜疾病組成。 肝功能障礙是致命的，可導致甲型肝炎,乙型肝炎,丙型肝炎,非酒精性脂肪肝,肝癌,膽管癌,肝細胞腺瘤,肝硬化等多種急慢性疾病。 肝病的原因包括感染（寄生蟲,病毒）,慢性酒精中毒,肝臟脂肪堆積,免疫系統異常和遺傳（血色素沉著症,高氧尿症,威爾遜氏病）。

診斷肝病的方法有多種，例如影像學檢查,臨床檢查,內窺鏡檢查和活組織檢查。 越來越多地使用診斷成像，如 MRI,CT 掃描和實驗室診斷肝病，正在推動肝病診斷市場的增長。

推動肝病診斷市場增長的主要因素包括不斷進步的技術進步,肝炎,慢性乙型肝炎,慢性丙型肝炎,非酒精性脂肪肝 (NAFLD) 等慢性肝病。例如，疾病的流行正在上升。 其他肝病包括浸潤性肝病（肝結節病,澱粉樣變性等）,ALPHA-1抗胰蛋白□缺乏症,原發性膽汁性膽管炎,原發性硬化性膽管炎。

例如，根據世界衛生組織 (WHO) 於 2022 年 6 月發布的一份報告，全球估計有 5800 萬人感染了慢性丙型肝炎病毒，每年約有 150 萬新病例。和 估計有 320 萬青少年和兒童感染慢性丙型肝炎。 這些因素增加了對肝病診斷劑的需求。

然而，不利的醫療費用,訓練有素的醫生和內窺鏡醫師短缺,活檢副作用以及與肝病診斷相關的高成本等並發症預計會阻礙市場增長。 另一方面，發展中國家未被滿足的醫療需求和新興國家有利的商機，未來有望為全球肝病診斷藥物生產企業帶來巨大商機。

此外，由於慢性肝病,肝炎和肝癌的患病率上升，對藥物發現和開發的研發投資不斷增加，以及對肝病微創診斷方法的認識不斷提高，預計醫療保健業務將會增長。因此，預計主要參與者在預測期內對該市場的投資將提供有利可圖的機會。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析

第 4 章肝病診斷市場：按技術分類

  • 概覽
    • 市場規模和預測
  • 成像
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 實驗室測試
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 內窺鏡檢查
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 活檢
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章肝病診斷市場：按最終用戶分類

  • 概覽
    • 市場規模和預測
  • 醫院
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 實驗室
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章肝病診斷市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機會
    • 北美市場規模和預測：按技術分類
    • 北美市場規模和預測：按最終用戶分類
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機會
    • 歐洲市場規模和預測：按技術分類
    • 歐洲市場規模和預測：按最終用戶分類
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太市場規模和預測：按技術分類
    • 亞太市場規模和預測：按最終用戶分類
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 中國
      • 日本
      • 印度
      • 韓國
      • 澳大利亞
      • 亞太其他地區
  • 拉美
    • 主要趨勢和機遇
    • LAMEA 市場規模和預測：按技術分類
    • LAMEA 市場規模和預測：按最終用戶分類
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他拉美地區

第七章商業條件

  • 介紹
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第八章公司簡介

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • Cosara Diagnostics Pvt Ltd
  • Echosens
  • Meril Life Sciences Pvt. Ltd.
  • PerkinElmer
  • Qiagen N.V.
  • Siemen's AG
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare
Product Code: A08425

The liver disease diagnostics market was valued at $34,520.4 million in 2021 and is estimated to reach $61,962.1 million by 2031, growing at a CAGR of 6.1% from 2022 to 2031. 

The liver is a vital organ of the body and has more than 500 functions and primary functions such as bile production & excretion, as excretion as bilirubin, cholesterol, hormones, and drugs. It fights infection, eliminates toxins, and helps in blood purification. Liver disease comprises a range of complex conditions that affect the liver. Liver dysfunction can be fatal and can cause a variety of acute and chronic disorders, including hepatitis A, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, liver cancer, bile duct cancer, liver cell adenoma, and liver cirrhosis. Liver diseases are caused due to infection (parasites and viruses), chronic alcohol abuse, fat accumulation in the liver, immune system abnormality, and inheritance (hemochromatosis, hyperoxaluria, and Wilson's disease)

Various techniques are used for the diagnosis of liver diseases such as imaging, laboratory tests, endoscopy, and biopsy. An increase in the use of imaging such as MRI, CT scan, and laboratory for the diagnosis of liver diseases boosts the growth of the liver disease diagnostics market.

Major factors that drive the growth of the liver disease diagnostics market include a rise in technological advancements, and an increase in the prevalence rate of chronic liver diseases such as hepatitis, chronic hepatitis B, chronic hepatitis C, and nonalcohol-related fatty liver disease (NAFLD). In addition, other liver diseases include infiltrative liver disorders (e.g., hepatic sarcoidosis and amyloidosis), alpha-1 antitrypsin deficiency, primary biliary cholangitis, and primary sclerosing cholangitis.

For instance, according to a report by the World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people had chronic hepatitis C virus infection, with around 1.5 million new infections occurring per year. An estimated 3.2 million adolescents and children have chronic hepatitis C infection. Hence, such factors increase the demand for liver disease diagnostics.

However, unfavorable reimbursements, as well as complications such as the dearth of trained physicians & endoscopists, side effects of biopsy, and high costs associated with liver disease diagnostic products, are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for liver disease diagnostics manufacturers worldwide in the future.

Furthermore, the healthcare business is projected to witness growth, owing to a rise in the prevalence of chronic liver diseases, hepatitis, and liver cancer; an increase in R&D investments in drug discovery & development, and a rise in awareness regarding the minimally invasive diagnostic procedure for liver diseases. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The liver disease diagnostics market is segmented on the basis of technique, end user, and region. On the basis of technique, the market is classified into imaging, laboratory tests, endoscopy, and biopsy. Depending on the end user, it is fragmented into hospitals, laboratories, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are Abbott Laboratories, Bio-Rad Laboratories Inc., Cosara Diagnostics Pvt Ltd, Echosens, Fujifilm Holdings Corporation, Meril Life Sciences Pvt. Ltd., Qiagen N.V., Siemens AG, Thermo Fisher Scientific Inc., and Trivitron Healthcare.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the liver disease diagnostics market analysis from 2021 to 2031 to identify the prevailing liver disease diagnostics market opportunities.

Market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the liver disease diagnostics market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global liver disease diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Technique

  • endoscopy
  • biopsy
  • imaging
  • laboratory tests

By End Use

  • hospitals
  • laboratories
  • others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Abbott Laboratories
    • Bio-Rad Laboratories Inc.
    • Cosara Diagnostics Pvt Ltd
    • Echosens
    • Meril Life Sciences Pvt. Ltd.
    • PerkinElmer
    • Qiagen N.V.
    • Siemen's AG
    • Thermo Fisher Scientific Inc.
    • Trivitron Healthcare

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 imaging
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 laboratory tests
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 endoscopy
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 biopsy
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country

CHAPTER 5: LIVER DISEASE DIAGNOSTICS MARKET, BY END USE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 hospitals
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 laboratories
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: LIVER DISEASE DIAGNOSTICS MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Technique
    • 6.2.3 North America Market size and forecast, by End Use
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Market size and forecast, by Technique
      • 6.2.4.1.2 Market size and forecast, by End Use
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Market size and forecast, by Technique
      • 6.2.4.2.2 Market size and forecast, by End Use
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Market size and forecast, by Technique
      • 6.2.4.3.2 Market size and forecast, by End Use
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Technique
    • 6.3.3 Europe Market size and forecast, by End Use
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Market size and forecast, by Technique
      • 6.3.4.1.2 Market size and forecast, by End Use
      • 6.3.4.2 France
      • 6.3.4.2.1 Market size and forecast, by Technique
      • 6.3.4.2.2 Market size and forecast, by End Use
      • 6.3.4.3 UK
      • 6.3.4.3.1 Market size and forecast, by Technique
      • 6.3.4.3.2 Market size and forecast, by End Use
      • 6.3.4.4 Italy
      • 6.3.4.4.1 Market size and forecast, by Technique
      • 6.3.4.4.2 Market size and forecast, by End Use
      • 6.3.4.5 Spain
      • 6.3.4.5.1 Market size and forecast, by Technique
      • 6.3.4.5.2 Market size and forecast, by End Use
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Market size and forecast, by Technique
      • 6.3.4.6.2 Market size and forecast, by End Use
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Technique
    • 6.4.3 Asia-Pacific Market size and forecast, by End Use
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 China
      • 6.4.4.1.1 Market size and forecast, by Technique
      • 6.4.4.1.2 Market size and forecast, by End Use
      • 6.4.4.2 Japan
      • 6.4.4.2.1 Market size and forecast, by Technique
      • 6.4.4.2.2 Market size and forecast, by End Use
      • 6.4.4.3 India
      • 6.4.4.3.1 Market size and forecast, by Technique
      • 6.4.4.3.2 Market size and forecast, by End Use
      • 6.4.4.4 South Korea
      • 6.4.4.4.1 Market size and forecast, by Technique
      • 6.4.4.4.2 Market size and forecast, by End Use
      • 6.4.4.5 Australia
      • 6.4.4.5.1 Market size and forecast, by Technique
      • 6.4.4.5.2 Market size and forecast, by End Use
      • 6.4.4.6 Rest of Asia-Pacific
      • 6.4.4.6.1 Market size and forecast, by Technique
      • 6.4.4.6.2 Market size and forecast, by End Use
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Technique
    • 6.5.3 LAMEA Market size and forecast, by End Use
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Market size and forecast, by Technique
      • 6.5.4.1.2 Market size and forecast, by End Use
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Market size and forecast, by Technique
      • 6.5.4.2.2 Market size and forecast, by End Use
      • 6.5.4.3 South Africa
      • 6.5.4.3.1 Market size and forecast, by Technique
      • 6.5.4.3.2 Market size and forecast, by End Use
      • 6.5.4.4 Rest of LAMEA
      • 6.5.4.4.1 Market size and forecast, by Technique
      • 6.5.4.4.2 Market size and forecast, by End Use

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 Abbott Laboratories
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 Bio-Rad Laboratories Inc.
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 Cosara Diagnostics Pvt Ltd
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 Echosens
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 Meril Life Sciences Pvt. Ltd.
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 PerkinElmer
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 Qiagen N.V.
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 Siemen's AG
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 Thermo Fisher Scientific Inc.
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 Trivitron Healthcare
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 2. LIVER DISEASE DIAGNOSTICS MARKET, FOR IMAGING, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. LIVER DISEASE DIAGNOSTICS MARKET FOR IMAGING, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. LIVER DISEASE DIAGNOSTICS MARKET, FOR LABORATORY TESTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. LIVER DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. LIVER DISEASE DIAGNOSTICS MARKET, FOR ENDOSCOPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. LIVER DISEASE DIAGNOSTICS MARKET FOR ENDOSCOPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. LIVER DISEASE DIAGNOSTICS MARKET, FOR BIOPSY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. LIVER DISEASE DIAGNOSTICS MARKET FOR BIOPSY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 11. LIVER DISEASE DIAGNOSTICS MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. LIVER DISEASE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. LIVER DISEASE DIAGNOSTICS MARKET, FOR LABORATORIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. LIVER DISEASE DIAGNOSTICS MARKET FOR LABORATORIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. LIVER DISEASE DIAGNOSTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. LIVER DISEASE DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. LIVER DISEASE DIAGNOSTICS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 19. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 20. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. U.S. LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 22. U.S. LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 23. CANADA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 24. CANADA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 25. MEXICO LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 26. MEXICO LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 27. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 30. GERMANY LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 31. GERMANY LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 32. FRANCE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 33. FRANCE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 34. UK LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 35. UK LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 36. ITALY LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 37. ITALY LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 38. SPAIN LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 39. SPAIN LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 40. REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 41. REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 42. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 43. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 44. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 45. CHINA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 46. CHINA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 47. JAPAN LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 48. JAPAN LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 49. INDIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 50. INDIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 51. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 52. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 53. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 54. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 55. REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 56. REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 57. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 58. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 59. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 60. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 61. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 62. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 63. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 64. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 65. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 66. REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
  • TABLE 67. REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 68.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 69.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 70.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 71.ABBOTT LABORATORIES: NET SALES,
  • TABLE 72.ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 73.BIO-RAD LABORATORIES INC.: COMPANY SNAPSHOT
  • TABLE 74.BIO-RAD LABORATORIES INC.: OPERATING SEGMENTS
  • TABLE 75.BIO-RAD LABORATORIES INC.: PRODUCT PORTFOLIO
  • TABLE 76.BIO-RAD LABORATORIES INC.: NET SALES,
  • TABLE 77.BIO-RAD LABORATORIES INC.: KEY STRATERGIES
  • TABLE 78.COSARA DIAGNOSTICS PVT LTD: COMPANY SNAPSHOT
  • TABLE 79.COSARA DIAGNOSTICS PVT LTD: OPERATING SEGMENTS
  • TABLE 80.COSARA DIAGNOSTICS PVT LTD: PRODUCT PORTFOLIO
  • TABLE 81.COSARA DIAGNOSTICS PVT LTD: NET SALES,
  • TABLE 82.COSARA DIAGNOSTICS PVT LTD: KEY STRATERGIES
  • TABLE 83.ECHOSENS: COMPANY SNAPSHOT
  • TABLE 84.ECHOSENS: OPERATING SEGMENTS
  • TABLE 85.ECHOSENS: PRODUCT PORTFOLIO
  • TABLE 86.ECHOSENS: NET SALES,
  • TABLE 87.ECHOSENS: KEY STRATERGIES
  • TABLE 88.MERIL LIFE SCIENCES PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 89.MERIL LIFE SCIENCES PVT. LTD.: OPERATING SEGMENTS
  • TABLE 90.MERIL LIFE SCIENCES PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 91.MERIL LIFE SCIENCES PVT. LTD.: NET SALES,
  • TABLE 92.MERIL LIFE SCIENCES PVT. LTD.: KEY STRATERGIES
  • TABLE 93.PERKINELMER: COMPANY SNAPSHOT
  • TABLE 94.PERKINELMER: OPERATING SEGMENTS
  • TABLE 95.PERKINELMER: PRODUCT PORTFOLIO
  • TABLE 96.PERKINELMER: NET SALES,
  • TABLE 97.PERKINELMER: KEY STRATERGIES
  • TABLE 98.QIAGEN N.V.: COMPANY SNAPSHOT
  • TABLE 99.QIAGEN N.V.: OPERATING SEGMENTS
  • TABLE 100.QIAGEN N.V.: PRODUCT PORTFOLIO
  • TABLE 101.QIAGEN N.V.: NET SALES,
  • TABLE 102.QIAGEN N.V.: KEY STRATERGIES
  • TABLE 103.SIEMEN'S AG: COMPANY SNAPSHOT
  • TABLE 104.SIEMEN'S AG: OPERATING SEGMENTS
  • TABLE 105.SIEMEN'S AG: PRODUCT PORTFOLIO
  • TABLE 106.SIEMEN'S AG: NET SALES,
  • TABLE 107.SIEMEN'S AG: KEY STRATERGIES
  • TABLE 108.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 109.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 110.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 111.THERMO FISHER SCIENTIFIC INC.: NET SALES,
  • TABLE 112.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
  • TABLE 113.TRIVITRON HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 114.TRIVITRON HEALTHCARE: OPERATING SEGMENTS
  • TABLE 115.TRIVITRON HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 116.TRIVITRON HEALTHCARE: NET SALES,
  • TABLE 117.TRIVITRON HEALTHCARE: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.LIVER DISEASE DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 2.LIVER DISEASE DIAGNOSTICS MARKET,2021-2031
  • FIGURE 3.LIVER DISEASE DIAGNOSTICS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.LIVER DISEASE DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.LIVER DISEASE DIAGNOSTICS MARKET,BY TECHNIQUE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF IMAGING LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF LABORATORY TESTS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF BIOPSY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 17.LIVER DISEASE DIAGNOSTICS MARKET,BY END USE,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF LABORATORIES LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
  • FIGURE 21.LIVER DISEASE DIAGNOSTICS MARKET BY REGION,2021
  • FIGURE 22.U.S. LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 23.CANADA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 24.MEXICO LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 25.GERMANY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 26.FRANCE LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 27.UK LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 28.ITALY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 29.SPAIN LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 30.REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 31.CHINA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 32.JAPAN LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 33.INDIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 34.SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 35.AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 36.REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 37.BRAZIL LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 38.SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 39.SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 40.REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45.COMPETITIVE DASHBOARD
  • FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 47.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
  • FIGURE 48.BIO-RAD LABORATORIES INC..: NET SALES ,($MILLION)
  • FIGURE 49.COSARA DIAGNOSTICS PVT LTD.: NET SALES ,($MILLION)
  • FIGURE 50.ECHOSENS.: NET SALES ,($MILLION)
  • FIGURE 51.MERIL LIFE SCIENCES PVT. LTD..: NET SALES ,($MILLION)
  • FIGURE 52.PERKINELMER.: NET SALES ,($MILLION)
  • FIGURE 53.QIAGEN N.V..: NET SALES ,($MILLION)
  • FIGURE 54.SIEMEN'S AG.: NET SALES ,($MILLION)
  • FIGURE 55.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)
  • FIGURE 56.TRIVITRON HEALTHCARE.: NET SALES ,($MILLION)